The Intelligence from The Economist Clotting factors: the AstraZeneca vaccine
Apr 8, 2021
Slavia Chankova, The Economist’s healthcare correspondent, shares insights on the AstraZeneca vaccine, highlighting regulatory findings on blood clot risks and public perceptions. Data journalist Elliot Morris discusses the lasting impact of the 1915 film "Birth of a Nation" on racial violence and how it shaped societal attitudes toward race. They also touch upon vaccine hesitancy stemming from these concerns. From vaccine safety to cinema's cultural ramifications, the conversation is both enlightening and provocative.
AI Snips
Chapters
Books
Transcript
Episode notes
AstraZeneca Vaccine and Blood Clots
- The AstraZeneca vaccine is linked to rare blood clots, especially in younger people and women.
- Regulators emphasize that the vaccine's benefits still outweigh the risks.
Transparency and Rare Side Effects
- Be aware that extremely rare side effects may emerge after millions of vaccinations.
- Regulators are transparent about risks and benefits.
Varying Responses to Vaccine Risks
- The UK offers alternative vaccines to under-30s, prioritizing COVID risk over the rare clotting risk.
- The EU leaves vaccine decisions to individual countries.
